| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms, Castration-Resistant | 13 | 2023 | 425 | 2.400 |
Why?
|
| Tissue Extracts | 6 | 2023 | 48 | 1.750 |
Why?
|
| Ipilimumab | 12 | 2021 | 710 | 1.640 |
Why?
|
| CTLA-4 Antigen | 13 | 2021 | 657 | 1.490 |
Why?
|
| Prostatic Neoplasms | 15 | 2023 | 5767 | 1.290 |
Why?
|
| Cancer Vaccines | 5 | 2021 | 697 | 1.140 |
Why?
|
| Immunotherapy | 14 | 2023 | 3341 | 0.960 |
Why?
|
| Antineoplastic Agents, Immunological | 5 | 2020 | 1249 | 0.920 |
Why?
|
| Immunotherapy, Active | 1 | 2019 | 46 | 0.680 |
Why?
|
| Antibodies, Monoclonal | 8 | 2023 | 4367 | 0.680 |
Why?
|
| Tumor Microenvironment | 12 | 2023 | 2864 | 0.680 |
Why?
|
| Neutrophils | 1 | 2021 | 835 | 0.590 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2021 | 598 | 0.540 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2020 | 1586 | 0.520 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 486 | 0.520 |
Why?
|
| B7-1 Antigen | 3 | 2005 | 88 | 0.500 |
Why?
|
| Abiraterone Acetate | 4 | 2023 | 70 | 0.500 |
Why?
|
| Clonal Evolution | 1 | 2016 | 253 | 0.500 |
Why?
|
| Immunomodulation | 1 | 2016 | 242 | 0.490 |
Why?
|
| Androgen Antagonists | 4 | 2021 | 411 | 0.430 |
Why?
|
| T-Lymphocyte Subsets | 5 | 2019 | 582 | 0.420 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2021 | 15862 | 0.400 |
Why?
|
| Colitis | 3 | 2019 | 340 | 0.400 |
Why?
|
| Biomarkers, Tumor | 8 | 2021 | 10331 | 0.400 |
Why?
|
| Antineoplastic Agents | 5 | 2023 | 14289 | 0.390 |
Why?
|
| Urogenital Neoplasms | 2 | 2021 | 108 | 0.370 |
Why?
|
| B7-H1 Antigen | 6 | 2023 | 1022 | 0.370 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 2330 | 0.350 |
Why?
|
| Programmed Cell Death 1 Receptor | 5 | 2019 | 1048 | 0.330 |
Why?
|
| Phenylthiohydantoin | 2 | 2022 | 89 | 0.320 |
Why?
|
| B7 Antigens | 2 | 2019 | 84 | 0.310 |
Why?
|
| Male | 38 | 2023 | 123000 | 0.300 |
Why?
|
| Antigens, CD | 4 | 2010 | 1385 | 0.300 |
Why?
|
| Lymphocyte Activation | 5 | 2021 | 1688 | 0.280 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2019 | 673 | 0.280 |
Why?
|
| Clinical Trials as Topic | 5 | 2023 | 3719 | 0.270 |
Why?
|
| Humans | 51 | 2023 | 261506 | 0.250 |
Why?
|
| Receptors, Tumor Necrosis Factor | 4 | 2005 | 184 | 0.230 |
Why?
|
| T-Lymphocytes | 6 | 2017 | 3869 | 0.230 |
Why?
|
| Th1 Cells | 3 | 2021 | 250 | 0.230 |
Why?
|
| Adenocarcinoma | 2 | 2019 | 7789 | 0.230 |
Why?
|
| Neoplasms | 8 | 2023 | 15193 | 0.230 |
Why?
|
| Blood Proteins | 1 | 2004 | 294 | 0.220 |
Why?
|
| Hypophysitis | 1 | 2021 | 10 | 0.200 |
Why?
|
| Toxicity Tests | 1 | 2021 | 50 | 0.200 |
Why?
|
| Listeria monocytogenes | 1 | 2021 | 52 | 0.200 |
Why?
|
| Kallikreins | 1 | 2021 | 84 | 0.200 |
Why?
|
| Adrenal Insufficiency | 1 | 2021 | 49 | 0.190 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 992 | 0.190 |
Why?
|
| Mobile Applications | 1 | 2021 | 100 | 0.180 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 709 | 0.180 |
Why?
|
| Radium | 1 | 2021 | 93 | 0.180 |
Why?
|
| Forkhead Transcription Factors | 3 | 2019 | 778 | 0.180 |
Why?
|
| Autoimmune Hypophysitis | 1 | 2019 | 13 | 0.180 |
Why?
|
| Cell Lineage | 2 | 2019 | 668 | 0.180 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2019 | 19 | 0.180 |
Why?
|
| Hypothyroidism | 1 | 2021 | 204 | 0.170 |
Why?
|
| Graft Rejection | 1 | 2004 | 834 | 0.170 |
Why?
|
| Bone Neoplasms | 3 | 2021 | 2576 | 0.170 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2019 | 101 | 0.170 |
Why?
|
| Melanoma, Experimental | 2 | 2019 | 368 | 0.170 |
Why?
|
| Prostatectomy | 2 | 2021 | 962 | 0.170 |
Why?
|
| Myocarditis | 1 | 2021 | 190 | 0.170 |
Why?
|
| Extracellular Vesicles | 1 | 2021 | 135 | 0.170 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2018 | 36 | 0.170 |
Why?
|
| Thyrotoxicosis | 1 | 2018 | 22 | 0.170 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2019 | 212 | 0.170 |
Why?
|
| Middle Aged | 19 | 2021 | 86204 | 0.160 |
Why?
|
| Autoantibodies | 2 | 2019 | 576 | 0.160 |
Why?
|
| Melanoma | 3 | 2018 | 5317 | 0.160 |
Why?
|
| Treatment Outcome | 8 | 2023 | 32848 | 0.160 |
Why?
|
| Peptides | 1 | 2004 | 1479 | 0.160 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2018 | 149 | 0.150 |
Why?
|
| Anilides | 1 | 2020 | 268 | 0.150 |
Why?
|
| Prostate-Specific Antigen | 1 | 2021 | 993 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 543 | 0.150 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 29902 | 0.150 |
Why?
|
| Cytokines | 5 | 2019 | 2809 | 0.150 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2019 | 278 | 0.150 |
Why?
|
| Aged | 17 | 2021 | 70117 | 0.150 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2018 | 245 | 0.150 |
Why?
|
| Pneumonia | 2 | 2020 | 751 | 0.140 |
Why?
|
| Immunosuppressive Agents | 1 | 2023 | 1375 | 0.140 |
Why?
|
| Receptors, Androgen | 2 | 2020 | 878 | 0.140 |
Why?
|
| Interleukin-7 | 1 | 2016 | 95 | 0.140 |
Why?
|
| Proton Pump Inhibitors | 1 | 2019 | 249 | 0.140 |
Why?
|
| Gene Expression | 3 | 2021 | 3570 | 0.140 |
Why?
|
| Radiography, Interventional | 1 | 2018 | 305 | 0.140 |
Why?
|
| Academies and Institutes | 1 | 2016 | 95 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 799 | 0.140 |
Why?
|
| Cohort Studies | 4 | 2021 | 9244 | 0.140 |
Why?
|
| Taxoids | 1 | 2019 | 967 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2022 | 1033 | 0.130 |
Why?
|
| Research Report | 1 | 2016 | 144 | 0.130 |
Why?
|
| Urologic Neoplasms | 1 | 2017 | 188 | 0.130 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 1301 | 0.130 |
Why?
|
| Disease Susceptibility | 2 | 2016 | 538 | 0.130 |
Why?
|
| Oncolytic Virotherapy | 2 | 2017 | 280 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2021 | 2803 | 0.130 |
Why?
|
| Congresses as Topic | 1 | 2016 | 298 | 0.120 |
Why?
|
| Gene Products, gag | 1 | 2013 | 36 | 0.120 |
Why?
|
| Immunity | 1 | 2016 | 342 | 0.120 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2016 | 665 | 0.120 |
Why?
|
| Endogenous Retroviruses | 1 | 2013 | 41 | 0.120 |
Why?
|
| Receptors, Nerve Growth Factor | 2 | 2003 | 31 | 0.110 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2013 | 112 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 10035 | 0.110 |
Why?
|
| Pyridines | 1 | 2020 | 1244 | 0.110 |
Why?
|
| RNA | 2 | 2021 | 1013 | 0.110 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2013 | 192 | 0.110 |
Why?
|
| Biomarkers | 3 | 2022 | 5047 | 0.110 |
Why?
|
| Interferon-gamma | 1 | 2016 | 1144 | 0.110 |
Why?
|
| Animals | 18 | 2021 | 59536 | 0.100 |
Why?
|
| Nitriles | 3 | 2023 | 906 | 0.100 |
Why?
|
| Patient Selection | 1 | 2019 | 2055 | 0.100 |
Why?
|
| Immunization, Passive | 1 | 2011 | 172 | 0.100 |
Why?
|
| Mice | 14 | 2021 | 34495 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 3251 | 0.100 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 1763 | 0.100 |
Why?
|
| Macrophages | 1 | 2017 | 1304 | 0.090 |
Why?
|
| Adoptive Transfer | 3 | 2017 | 446 | 0.090 |
Why?
|
| Autoimmune Diseases | 2 | 2004 | 402 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 7 | 2018 | 6942 | 0.090 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2018 | 907 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 3821 | 0.090 |
Why?
|
| Mice, Transgenic | 5 | 2018 | 4143 | 0.080 |
Why?
|
| Cell Line, Tumor | 6 | 2021 | 14551 | 0.080 |
Why?
|
| Prednisone | 2 | 2021 | 984 | 0.080 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2018 | 2341 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 3230 | 0.070 |
Why?
|
| Heart Failure | 1 | 2021 | 2516 | 0.070 |
Why?
|
| Diarrhea | 2 | 2020 | 686 | 0.070 |
Why?
|
| Prognosis | 4 | 2020 | 21713 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 4320 | 0.070 |
Why?
|
| Immunologic Memory | 2 | 2019 | 374 | 0.070 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 2 | 2005 | 96 | 0.070 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 5112 | 0.070 |
Why?
|
| Retrospective Studies | 7 | 2021 | 37905 | 0.060 |
Why?
|
| Immune System | 2 | 2018 | 279 | 0.060 |
Why?
|
| Liver Regeneration | 1 | 2005 | 134 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2016 | 11965 | 0.060 |
Why?
|
| Succinimides | 1 | 2004 | 7 | 0.060 |
Why?
|
| Receptors, Virus | 1 | 2005 | 157 | 0.060 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2004 | 35 | 0.060 |
Why?
|
| Fluoresceins | 1 | 2004 | 73 | 0.060 |
Why?
|
| Time Factors | 3 | 2021 | 12926 | 0.060 |
Why?
|
| Fatigue | 2 | 2021 | 1239 | 0.060 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2010 | 1283 | 0.060 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2003 | 186 | 0.060 |
Why?
|
| CD3 Complex | 1 | 2004 | 314 | 0.060 |
Why?
|
| CD40 Antigens | 1 | 2003 | 104 | 0.060 |
Why?
|
| Benzamides | 2 | 2022 | 1832 | 0.060 |
Why?
|
| Islets of Langerhans | 1 | 2004 | 229 | 0.060 |
Why?
|
| Cell Division | 2 | 2004 | 2489 | 0.050 |
Why?
|
| CD28 Antigens | 1 | 2003 | 202 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2004 | 869 | 0.050 |
Why?
|
| Membrane Glycoproteins | 2 | 2004 | 1073 | 0.050 |
Why?
|
| Autoimmunity | 1 | 2004 | 263 | 0.050 |
Why?
|
| Immune Tolerance | 1 | 2004 | 403 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2019 | 3033 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2004 | 459 | 0.050 |
Why?
|
| Lymphoma, T-Cell | 1 | 2004 | 361 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 769 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2019 | 9180 | 0.050 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2021 | 156 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 14889 | 0.050 |
Why?
|
| Hydrolases | 1 | 2021 | 123 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 3639 | 0.050 |
Why?
|
| Female | 11 | 2021 | 141928 | 0.050 |
Why?
|
| Neoplasm Transplantation | 2 | 2014 | 1519 | 0.050 |
Why?
|
| Androstenes | 1 | 2020 | 41 | 0.050 |
Why?
|
| Headache | 1 | 2021 | 163 | 0.050 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2019 | 37 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 3 | 2016 | 2314 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 657 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 5178 | 0.040 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 7222 | 0.040 |
Why?
|
| Hypokalemia | 1 | 2019 | 55 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2004 | 1244 | 0.040 |
Why?
|
| Dehydration | 1 | 2019 | 87 | 0.040 |
Why?
|
| Survival Rate | 3 | 2021 | 12221 | 0.040 |
Why?
|
| Receptors, IgG | 1 | 2019 | 102 | 0.040 |
Why?
|
| Antigens | 1 | 2019 | 292 | 0.040 |
Why?
|
| Thyroid Function Tests | 1 | 2018 | 38 | 0.040 |
Why?
|
| Osteoclasts | 1 | 2019 | 165 | 0.040 |
Why?
|
| Anorexia | 1 | 2019 | 143 | 0.040 |
Why?
|
| Random Allocation | 1 | 2020 | 703 | 0.040 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2021 | 565 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 1555 | 0.040 |
Why?
|
| Clone Cells | 1 | 2019 | 555 | 0.040 |
Why?
|
| Homeostasis | 1 | 2003 | 950 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2021 | 324 | 0.040 |
Why?
|
| Forecasting | 1 | 2021 | 694 | 0.040 |
Why?
|
| Exosomes | 1 | 2021 | 253 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2018 | 226 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2021 | 615 | 0.040 |
Why?
|
| Adult | 5 | 2021 | 77950 | 0.040 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2016 | 44 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2019 | 7226 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 1183 | 0.040 |
Why?
|
| Dasatinib | 1 | 2020 | 862 | 0.040 |
Why?
|
| Carboplatin | 1 | 2019 | 823 | 0.040 |
Why?
|
| California | 1 | 2016 | 208 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 1290 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2004 | 830 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2021 | 5637 | 0.030 |
Why?
|
| Comprehension | 1 | 2016 | 120 | 0.030 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 14 | 2 | 2005 | 4 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2016 | 2450 | 0.030 |
Why?
|
| Membrane Proteins | 3 | 2017 | 2819 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 3472 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2018 | 598 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 2488 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2017 | 760 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 4654 | 0.030 |
Why?
|
| Neutropenia | 1 | 2019 | 968 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 750 | 0.030 |
Why?
|
| Lymphocytes | 2 | 2014 | 1234 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2017 | 1062 | 0.030 |
Why?
|
| Newcastle disease virus | 1 | 2014 | 7 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2017 | 1618 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 846 | 0.030 |
Why?
|
| Mice, Knockout | 4 | 2005 | 5710 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 2315 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 1130 | 0.030 |
Why?
|
| Anemia | 1 | 2019 | 689 | 0.030 |
Why?
|
| Survival | 1 | 2013 | 177 | 0.030 |
Why?
|
| Biopsy | 1 | 2021 | 3443 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2013 | 169 | 0.030 |
Why?
|
| Inflammation | 2 | 2014 | 2522 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 1439 | 0.030 |
Why?
|
| Piperidines | 1 | 2018 | 1035 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2014 | 250 | 0.030 |
Why?
|
| Castration | 1 | 2012 | 122 | 0.030 |
Why?
|
| Indoles | 1 | 2018 | 1009 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2018 | 1081 | 0.030 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 2 | 2003 | 69 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 669 | 0.030 |
Why?
|
| Spleen | 2 | 2005 | 676 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2020 | 12873 | 0.030 |
Why?
|
| Oncolytic Viruses | 1 | 2014 | 204 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 4821 | 0.020 |
Why?
|
| Heterografts | 1 | 2013 | 733 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 7548 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 1879 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 6207 | 0.020 |
Why?
|
| Texas | 1 | 2021 | 6311 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2004 | 5270 | 0.020 |
Why?
|
| Antibodies | 1 | 2013 | 838 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2013 | 1643 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2005 | 1538 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 10001 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2019 | 6100 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 8865 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 5159 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2014 | 904 | 0.020 |
Why?
|
| Genomics | 1 | 2017 | 2738 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 3101 | 0.020 |
Why?
|
| Lymphotoxin beta Receptor | 1 | 2005 | 3 | 0.020 |
Why?
|
| Hepatomegaly | 1 | 2005 | 69 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2005 | 6 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2005 | 182 | 0.020 |
Why?
|
| Concanavalin A | 1 | 2005 | 67 | 0.020 |
Why?
|
| Ethylnitrosourea | 1 | 2004 | 19 | 0.020 |
Why?
|
| Transcriptome | 1 | 2013 | 1859 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2004 | 125 | 0.020 |
Why?
|
| B7-2 Antigen | 1 | 2003 | 55 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2017 | 4975 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 2004 | 205 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2013 | 2669 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2005 | 351 | 0.010 |
Why?
|
| Ligands | 1 | 2005 | 995 | 0.010 |
Why?
|
| Myelin-Associated Glycoprotein | 1 | 2002 | 17 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 4053 | 0.010 |
Why?
|
| Disease Progression | 1 | 2013 | 6682 | 0.010 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2002 | 38 | 0.010 |
Why?
|
| Thymus Gland | 1 | 2003 | 294 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2002 | 197 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 2002 | 117 | 0.010 |
Why?
|
| Myelin Proteins | 1 | 2002 | 90 | 0.010 |
Why?
|
| DNA Replication | 1 | 2005 | 744 | 0.010 |
Why?
|
| Mice, Inbred NOD | 1 | 2003 | 905 | 0.010 |
Why?
|
| Oncogenes | 1 | 2004 | 673 | 0.010 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2002 | 219 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2002 | 626 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2004 | 1338 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2003 | 842 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2002 | 329 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 21445 | 0.010 |
Why?
|
| Hepatectomy | 1 | 2005 | 1011 | 0.010 |
Why?
|
| Cell Survival | 1 | 2003 | 3045 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 4233 | 0.010 |
Why?
|
| Risk Factors | 1 | 2012 | 17523 | 0.010 |
Why?
|
| Liver | 1 | 2005 | 2961 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 6089 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2004 | 6150 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2003 | 2967 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2003 | 4078 | 0.010 |
Why?
|